Form 8-K - Current report:
SEC Accession No. 0001193125-25-032821
Filing Date
2025-02-24
Accepted
2025-02-24 08:14:04
Documents
15
Period of Report
2025-02-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d889659d8k.htm   iXBRL 8-K 42836
2 EX-99.1 d889659dex991.htm EX-99.1 12325
6 GRAPHIC g889659g0224005037687.jpg GRAPHIC 3147
  Complete submission text file 0001193125-25-032821.txt   196892

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ikt-20250221.xsd EX-101.SCH 2857
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20250221_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20250221_pre.xml EX-101.PRE 11713
17 EXTRACTED XBRL INSTANCE DOCUMENT d889659d8k_htm.xml XML 3768
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 25654303
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)